HE4检测对卵巢癌手术结果的预测分析  

Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients

作　　者：惠慧 吴磊[1,2] 杨新园[2] 

机构地区：[1]陕西省肿瘤医院妇瘤科,陕西西安710061 [2]西安交通大学第一附属医院妇产科,陕西西安710061

出　　处：《西部医学》2015年第5期751-752,755,共3页Medical Journal of West China

摘　　要：目的探讨人附睾蛋白4(HE4)在预测卵巢癌手术结果中的价值。方法收集77例卵巢癌患者术前血清标本,采用酶联免疫吸附测定法测定HE4的血清表达水平,分析其与术后肿瘤残存的关系。结果术前血清HE4值与肿瘤残存体积呈正相关(P<0.05),而术前CA125检测值与肿瘤残存体积无统计学意义(P>0.05)。结论术前HE4值可以预测卵巢癌的手术结果,且与手术残存体积呈正相关。Objectives The aim of our study was to analyze the role of HE4 in predicting surgical and clinical out- come in primary ovarian cancer. Methods 77 patients with primary EOC were enrolled. Patients were eligible if radical cytoreductive surgery was performed. Plasma samples were collected before. The concentrations of HE4 and CA125 was determined using ELISA. Te postoperative specimens removed based on the results of post-operative pathologic and imaging. Results Higher plasma HE41eve was correlated with poor surgery outcome in terms of macroscopically residual tumor mass （P〈0.05）. Plasma CA125 was not predictive factors for surgical outcome（P〉0.05）. Conclusion Preopera- tive HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients.

关 键 词：卵巢癌 HE4 CA125 肿瘤残存体积 

分 类 号：R737.32[医药卫生—肿瘤]